Format

Send to

Choose Destination
Br J Cancer. 2011 Mar 29;104(7):1079-84. doi: 10.1038/bjc.2011.43. Epub 2011 Mar 8.

FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.

Author information

1
Oncology, Haematology and Respiratory Diseases Department, University Hospital of Modena, Modena, Italy. bertolini.federica@policlinico.mo.it

Abstract

BACKGROUND:

In patients with colorectal liver metastases (CLM) R0 resection significantly improves overall survival (OS).

METHODS:

In this report, we present the results of a phase II trial of FOLFOX6+bevacizumab in patients with non-optimally resectable CLM. Patients received six cycles of FOLFOX6+ five of bevacizumab. Patients not achieving resectability received six additional cycles of each. A PET-CT was performed at baseline and again within 1 month after initiating treatment.

RESULTS:

From September 2005 to July 2009, 21 patients were enrolled (Male/Female: 15/6; median age: 65 years). An objective response (OR) was documented in 12 cases (57.1%; complete responses (CRs): 3, partial response (PR): 9); one patient died from toxicity before surgery. Thirteen patients underwent radical surgery (61.9%). Three (23%) had a pathological CR (pCR). Six patients (46.1%) experienced minor postsurgical complications. After a median 38.8-month follow-up, the median OS was 22.5 months. Patients achieving at least 1 unit reduction in Standard uptake value (SUV)max on PET-CT had longer progression-free survival (PFS) (median PFS: 22 vs 14 months, P=0.001).

CONCLUSIONS:

FOLFOX6+bevacizumab does not increase postsurgical complications, yields high rates of resectability and pCR. Early changes in PET-CT seem to be predictive of longer PFS.

PMID:
21386839
PMCID:
PMC3068493
DOI:
10.1038/bjc.2011.43
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center